Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8028724 | 0.87 | CNR1 (0.42) | NR1H2HDAC1HDAC6TAS2R8ALDH1A1 | |
| SCHEMBL8032968 | 0.84 | NR1H2 (0.43) | NR1H2HDAC1HDAC6TAS2R8 | |
| SCHEMBL8006342 | 0.84 | HDAC1 (0.38) | IGF1RNR1H2PTGS2PTGS1HDAC1 | |
| SCHEMBL1775167 | 0.83 | IGF1R (0.49) | IGF1RPTGS2PTGS1TAS2R8PRMT5 | |
| SCHEMBL1772486 | 0.83 | DRD2 (0.44) | IGF1RNR1H2TAS2R8ALDH1A1DRD2 | |
| SCHEMBL8037450 | 0.81 | HDAC1 (0.38) | NR1H2HDAC1HDAC6TAS2R8ALDH1A1 | |
| SCHEMBL12603186 | 0.80 | TP53 (0.41) | NR1H2HDAC1HDAC6TAS2R8ALDH1A1 | |
| SCHEMBL8031790 | 0.80 | NR1H2 (0.47) | IGF1RNR1H2HDAC1HDAC6TAS2R8 | |
| SCHEMBL12603214 | 0.79 | NR1H2 (0.43) | NR1H2HDAC1HDAC6TAS2R8DRD2 | |
| SCHEMBL12603210 | 0.78 | ITGB2 (0.46) | IGF1RNR1H2TAS2R8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| WO-2009097997-A1 | SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | GIPR, PGC, DDC | GLA 2197/4885IGF1R 189/4885NR1H2 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.